News Three's a crowd as Tecentriq approved in lung cancer Cancer immunotherapy approved in second line.
News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News New breakthrough designations for Roche's Alecensa and Actem... Alecensa and Roactemra are breakthroughs, says FDA.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News AZ's Tagrisso first to be funded through new Cancer Drugs Fu... New-look CDF pays for lung drug Tagrisso
News Owlstone's breath-based lung cancer diagnostic could save 10... Trial's next phase will recruit 3,000 patients across 21 international sites.
News Lilly strikes $8.8bn-plus alliance with China's Innovent Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
